Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Maslin

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Medicine (London, England)|February 3, 2016
Lesson of the month 2: Cauda equina in Cushing's syndromeDouglas Maslin, Ioannis Gounaris, Kenrick Ng, et al.
Journal of Medical Economics|May 27, 2026
Budget impact analysis of delgocitinib for moderate to severe Chronic Hand Eczema in the United StatesJianni Singh-Landa, Aseel Bin Sawad, Yasmin Bappoo, et al.
Frontiers in Medicine|May 30, 2024
A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of <i>Prevotella histicola</i>, in adults with mild-to-moderate plaque psoriasisBenjamin D Ehst, Bruce Strober, Andrew Blauvelt, et al.
Contact Dermatitis|March 3, 2026
Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand EczemaAndrea Bauer, Lyn Guenther, Richard Woolf, et al.
Dermatology and Therapy|June 12, 2026
Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice ExperimentApril W Armstrong, Aseel Bin Sawad, Nisha C Hazra, et al.
Dermatology and Therapy|November 15, 2025
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand EczemaDavid Cohen, Anthony Bewley, Andreas Wollenberg, et al.
Dermatology and Therapy|May 17, 2026
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 TrialMelinda Gooderham, Christopher G Bunick, JiaDe Yu, et al.
Dermatology and Therapy|September 26, 2025
Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart ReviewAna Giménez-Arnau, Anthony Bewley, Christian Apfelbacher, et al.
The Journal of Dermatological Treatment|January 6, 2026
Moderate to severe Chronic Hand Eczema in clinical practice: etiological subtypes, clinical signs and symptoms, and comorbidities-results from the RWEAL studyMaria Concetta Fargnoli, Sonja Molin, Anthony Bewley, et al.
Frontiers in Medicine|May 22, 2023
Clinical translation of anti-inflammatory effects of <i>Prevotella histicola</i> in Th1, Th2, and Th17 inflammationAndrea Itano, Douglas Maslin, Kritika Ramani, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Medicine (London, England)|February 3, 2016
Lesson of the month 2: Cauda equina in Cushing's syndromeDouglas Maslin, Ioannis Gounaris, Kenrick Ng, et al.
Journal of Medical Economics|May 27, 2026
Budget impact analysis of delgocitinib for moderate to severe Chronic Hand Eczema in the United StatesJianni Singh-Landa, Aseel Bin Sawad, Yasmin Bappoo, et al.
Frontiers in Medicine|May 30, 2024
A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of <i>Prevotella histicola</i>, in adults with mild-to-moderate plaque psoriasisBenjamin D Ehst, Bruce Strober, Andrew Blauvelt, et al.
Contact Dermatitis|March 3, 2026
Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand EczemaAndrea Bauer, Lyn Guenther, Richard Woolf, et al.
Dermatology and Therapy|June 12, 2026
Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice ExperimentApril W Armstrong, Aseel Bin Sawad, Nisha C Hazra, et al.
Dermatology and Therapy|November 15, 2025
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand EczemaDavid Cohen, Anthony Bewley, Andreas Wollenberg, et al.
Dermatology and Therapy|May 17, 2026
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 TrialMelinda Gooderham, Christopher G Bunick, JiaDe Yu, et al.
Dermatology and Therapy|September 26, 2025
Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart ReviewAna Giménez-Arnau, Anthony Bewley, Christian Apfelbacher, et al.
The Journal of Dermatological Treatment|January 6, 2026
Moderate to severe Chronic Hand Eczema in clinical practice: etiological subtypes, clinical signs and symptoms, and comorbidities-results from the RWEAL studyMaria Concetta Fargnoli, Sonja Molin, Anthony Bewley, et al.
Frontiers in Medicine|May 22, 2023
Clinical translation of anti-inflammatory effects of <i>Prevotella histicola</i> in Th1, Th2, and Th17 inflammationAndrea Itano, Douglas Maslin, Kritika Ramani, et al.
Pageof 2